Actelion shares fall on report it rejects J&J offer
- Dollar lower, stocks flat as caution creeps in ahead of Trump inauguration
- General Electric (GE) Reports In-Line Q4 EPS
- Procter & Gamble (PG) Tops Q2 EPS by 2c
- IBM (IBM) Tops Q4 EPS by 13c, FY17 EPS Guidance Beats Consensus
- American Express (AXP) Misses Q4 EPS by 7c, FY17 EPS Guidance Tops Views at Mid-Poinit
A general view shows Swiss biotech group Actelion Headquarters in Allschwil near Basel February 17, 2015. REUTERS/Arnd Wiegmann
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
ZURICH (Reuters) - Shares in Swiss biotech company Actelion fell more than 6 percent after news outlet streetinsider.com reported on Wednesday the company had rejected a full takeover offer by U.S. healthcare group Johnson & Johnson and may sell a unit.
Actelion declined to comment on the report, which cited an unidentified source, and referred to a statement the company had published on Friday. The companies had confirmed last week they were in talks about a possible transaction.
(Reporting by Paul Arnold, Editing by Michael Shields)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- P&G profit and sales beat Wall Street estimates
- 'Trump trades' on ice ahead of U.S. inauguration: BAML
- GE profit up 36 percent, sales slow; affirms 2017 forecast
Create E-mail Alert Related CategoriesReuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!